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The availability of HIV-1 genotype resistance testing (GRT) to clinicians has been insufficiently studied outside randomized
clinical trials. The present study evaluated the outcome of salvage antiretroviral therapy (ART) recommended by an expert
physician based on GRT in a non-clinical trial setting in Ribeirão Preto, Brazil. A prospective, open, nonrandomized study
evaluating easy access to GRT at six Brazilian AIDS Clinics was carried out. This cooperative study analyzed the efficacy of
treatment recommended to patients whose salvage ART was guided by GRT with that of treatment with ART based only on
previous ART history. A total of 112 patients with ART failure were included in the study, and 77 of them were submitted to GRT.
The median CD4 cell count and viral load for these 77 patients at baseline were (mean ± SD) 252.1 ± 157.4 cells/µL and 4.60
± 0.5 log10 HIV RNA copies/mL, respectively. The access time, i.e., the time elapsed between ordering the GRT and receiving
the result was, on average, 71.9 ± 37.3 days. The study results demonstrated that access to GRT followed by expert
recommendations did not improve the time to persistent treatment failure when compared to conventional salvage ART. Access
to GRT in this Brazilian community health care setting did not improve the long-term virologic outcomes of HIV-infected patients
experiencing treatment failure. This result is probably related to the long time required to implement ART guided by GRT.
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Introduction
Resistance to antiretroviral therapy (ART) is an impor-
tant cause of treatment failure among HIV-1-infected pa-
tients (1,2). HIV-1 genetic polymorphisms associated with
drug resistance have been retrospectively shown to be
associated with treatment failure, the development of AIDS,
and death (3-7). Prospective studies have shown short-
term improvement in virus load suppression when geno-
type testing was used to guide therapy in naive and expe-
rienced patients (8-11). Other recent studies have shown
either transient improvement (12) or no benefit (13,14)
associated with the use of genotype testing, i.e., resis-
tance assays.
Brazilian HIV-1-infected patients have had free access
to ART since the early 1990’s, a policy that has been
associated with a decrease in HIV-related mortality and
morbidity (15-17). The Brazilian Ministry of Health has
recently established the National Network for HIV-1 Geno-
typing (RENAGENO), and has recommended HIV-1 geno-
type resistance testing (GRT) in association with recom-
mendations by an expert physician to be used at AIDS
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Clinics to guide ART for patients with treatment failure (18).
Even though GRT has been validated in randomized
clinical trials, there are concerns about the feasibility of its
routine use and long-term efficacy in the management of
HIV-1 infection in community settings. The present study
investigates the impact of GRT on the selection of appro-
priate treatment for patients experiencing ART failure at
selected Brazilian AIDS Clinics.
Patients and Methods
HIV-1-infected patients were followed at AIDS Clinics
of the public health system of Ribeirão Preto, SP, Brazil.
They were eligible for this study if they were older than 18
years, had been receiving a failing ART regimen contain-
ing 3 or more drugs for at least 8 weeks before enrollment,
and were willing to attend regular medical appointments. A
failing ART regimen was defined as a viral load (VL) of
more than 3.0 log10 HIV-1 RNA copies/mL concomitant
with one or more of the following conditions: less than a 1.0
log10 reduction in VL 4 weeks after starting a therapy
regimen, failure to suppress VL to less than 400 HIV-1
RNA copies/mL 6 weeks after starting therapy, detection of
a plasma VL of more than 3.0 log10 HIV-1 RNA copies/mL
after initial suppression to less than 400 copies/mL, or an
increase of more than 0.5 log10 HIV-1 RNA copies/mL from
the nadir VL that could not be directly attributed to vaccina-
tion or intercurrent illness. The lower limit of 3.0 log10 HIV-
1 RNA copies/mL was chosen to minimize the effects of VL
“blips” on the study and to reflect the performance limits of
the resistance assay. Failure criteria were not mutually
exclusive. All treatment failures were confirmed with a
second VL measurement.
Six AIDS Clinics participated in the study, one located at
the University Hospital of the School of Medicine of Ribeirão
Preto, University of São Paulo (HC, FMRP, USP), and 5
being municipal health care centers. The protocol and con-
sent form were approved by the institutional Ethics Review
Board of HC, FMRP, USP. Patients were screened from
December 2001 through November 2002, and those meet-
ing the eligibility criteria were divided into two groups for
analysis (Figure 1). The first group (DI) consisted of a cohort
of patients undergoing ART failure who were submitted to
salvage ART guided by GRT with interpretation and recom-
mendations offered by an infectious disease physician. This
study group consisted of a 24-month prospective, non-
comparative study. The second group (DII) consisted of
patients whose salvage ART was guided by GRT (subgroup
G) and by those whose salvage ART was guided by clinical
management without resistance testing (subgroup C). This
study group consisted of a 24-month prospective, open, and
comparative study designed to evaluate the long-term effi-
cacy of salvage ART prescribed to patients undergoing ART
failure. Patients in subgroup G were screened from the DI
group. The DII group included patients only from the HC,
FMRP, USP. The overall retention rate in both study groups
was defined as the number of patients who did not reach the
end-point.
Access to GRT was evaluated as the time elapsed from
ordering the test by the attending physicians to receiving
the final result of the test. Efficacy of GRT was evaluated
by comparing salvage ART guided by GRT with conven-
tional salvage ART based only on the previous treatment
history. Participants were evaluated by routine medical
appointments every 3-4 months. At each visit, plasma VL
was measured using either the Quantiplex b-DNA (Chiron,
Emervyille, CA, USA) or NASBA/Nuclisens (Organon Tek-
nika, Boxtel, The Netherlands) assay according to manu-
facturer directions. A VL value below the detection limit of
400 HIV-1 RNA copies/mL was considered to be a re-
sponse to therapy.
The study algorithm for evaluating the efficacy of GRT
defined the end-point as refractory treatment failure. To
Figure 1. Flow chart of the study involving the following groups:
a cohort of patients on treatment failure submitted to genotype
resistance testing (GRT) to help guide a new antiretroviral thera-
py (ART) (DI), and a cohort of patients devised to compare the
long-term efficacy of new ART guided by GRT versus new ART
based on clinical judgment alone (DII). Subgroup G included
patients submitted to salvage ART guided by GRT, and were
screened from the DI group. Subgroup C included patients sub-
mitted to salvage ART guided by clinical management without
resistance testing. The DII group included patients only from the
University Hospital of the School of Medicine of Ribeirão Preto,
University of São Paulo (HC, FMRP, USP).
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reach an end-point, confirmed treatment failure had to be
determined during two consecutive routine appointments,
and a subsequent reevaluation appointment. GRT was
performed with the ViroSeq HIV-1 Genotyping System kit
(Applied Biosystems Inc., Foster City, CA, USA) according
to manufacturer instructions.
The analysis of efficacy was performed according to
the intent-to-treat principle. Baseline variables were com-
pared using the Student t-test and the Fisher exact test for
continuous and categorical variables, respectively. The
log-rank test was used to compare the time to end-point
between study subgroups. Nonparametric product-limit
estimation (Kaplan-Meier) was used to estimate the time to
end-point survival function. Univariate analysis was used
to evaluate the effects of sex, CD4 cell count, exposure to
non-nucleoside reverse-transcriptase inhibitors (NNRTIs),
initial plasma HIV RNA load, and previous ART experience
on the durability of virus suppression in the cohort of
patients submitted to GRT. All data were collected with
standardized questionnaires and entered into a database.
Statistical analyses were performed using the GraphPad
InStat and Prism software version 3.0 (GraphPad Soft-
ware, Inc., San Diego, CA, USA).
Results
Seventy-seven adults (45.5% women) were submitted
to GRT. The median CD4 cell count at baseline ± SD was
252.1 ± 157.4 cells/µL. The median VL at baseline ± SD
was 4.60 ± 0.5 log10 HIV RNA copies/mL. The median time
of previous antiretroviral exposure ± SD was 47.9 ± 22.6
months for nucleoside reverse transcriptase inhibitors,
36.5 ± 16.5 months for protease inhibitors, and 15.6 ± 10.0
months for NNRTI. All classes of antiretroviral drugs avail-
able in Brazil at the time of the study had been used at least
once by the patients (Table 1).
The mean turn-around time (access time) for receiving
the results of the resistance test assay was 71.9 ± 37.3
days. The mean time elapsed from ordering GRT by clini-
cians from health care facilities to the date of ART change
guided by the test was 132.2 ± 70.3 days. Only 1 patient
(1.2%) presented a wild-type virus sequence. Seven of the
77 patients (9.1%) were not submitted to salvage ART
despite availability of GRT results because 2 of them
achieved undetectable HIV-1 RNA levels on their current
regimen, 2 died, and 3 discontinued follow-up before sal-
vage ART. Four other patients (5.2%) had the ART changed
before receiving the test result. Thus, salvage ART guided
by GRT was initiated for 66 patients. Expert recommenda-
tions for salvage ART were adopted by attending physi-
cians for 56 patients (84.8%). A total of 4 patients (6%)
discontinued participation in the study for reasons other
than having reached the study end-point. The estimated
time to reach the end-point in the intent-to-treat analysis of
these 66 patients is shown on Figure 2. Median and mean
times to reach the end-point for the 62 patients kept on
treatment were 316.5 and 397 days, respectively. The
overall retention rate for the cohort at 12 and 24 months
was 28 (42.4%) and 23 patients (34.8%), respectively.
Univariate analysis demonstrated that male gender, na-
ive status for NNRTI, a history of less than four ART, plasma
Figure 2. Estimated time to reach the end-point curve in the
intent-to-treat analysis of 66 patients submitted to salvage anti-
retroviral therapy guided by genotype resistance testing (DI
group). The estimated percentage of subjects not reaching the
end-point is indicated on the y-axis, and the time to end-point is
indicated on the x-axis.
Table 1. Antiretroviral drugs previously administered to 77 pa-
tients who had access to genotype resistance testing.
Antiretroviral drug Patients (N) %
NRTI 77 100.0%
AZT (zidovudine) 76 98.7%
3TC (lamivudine) 71 92.2%
ddI (didanosine) 54 70.1%
d4T (stavudine) 41 53.2%
ddC (zalcitabine) 16 20.7%
NNRTI 28 36.3%
NVP (nevirapine) 12 15.5%
EFV (efavirenz) 20 26.0%
PI 76 98.7%
SQV (sequinavir) 22 28.5%
RTV (ritonavir) 25 32.4%
IDV (indinavir) 57 74.0%
NFV (nelfinavir) 41 53.2%
APV (amprenavir) 1 1.3%
NRTI = nucleoside reverse-transcriptase inhibitor; NNRTI = non-
nucleoside reverse-transcriptase inhibitor; PI = protease inhibitor.
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Table 2. Baseline demographic and clinical characteristics of 70 patients who had
access to salvage antiretroviral therapy (subgroup G) or not (subgroup C) accord-
ing to expert recommendations based on genotype resistance testing (GRT).
Characteristic Subgroup G (N = 35) Subgroup C (N = 35)
Age (years) 39.6 ± 8.7 35 ± 4.8*
Gender
Male 20 (57%) 20 (57%)
Female 15 (43%) 15 (43%)
Race
White 23 (66%) 26 (74%)
Black 11 (32%) 9 (26%)
Asian 1 (2%) 0 (0%)
CD4 cell count (cells/mL)a 209.9 ± 185.6 172.6 ± 143.8
Virus load (log10 copies/mL)a 4.7 ± 0.6 4.8 ± 0.8
CDC HIV stage
A 2 (5.7%) 1 (2.8%)
B 5 (14.3%) 5 (14.3%)
C 28 (80%) 29 (82.9%)
ART experience (months) 50.5 ± 22.8 40 ± 22*
ART experience to PI (months)b 39.7 ± 15.8 34.2 ± 18.1
ART experience to NRTI (months)c 8.1 ± 11.3 3.9 ± 8.1
NNRTI experienced 14 (40%) 12 (34%)
Data are reported as mean ± SD and as number with percent in parentheses of
patients at enrollment. Categorical variables were compared using the Fisher exact
test, and continuous variable was compared using the Student t-test (*P < 0.05, **P
< 0.054). CDC = Centers for Disease Control and Prevention; ART = antiretroviral
therapy; PI = protease inhibitor; NRTI = nucleoside reverse-transcriptase inhibitor;
NNRTI = non-nucleoside reverse-transcriptase inhibitor. aValues immediately be-
fore GRT. bART experience to PI = period of time of previous exposure to PI. cART
experience to NRTI = period of time of previous exposure to NRTI.
HIV-1 VL <50,000 RNA copies/mL, and CD4
cell count ≥200/mL were associated with
longer times to reach the end-point of thera-
py failure when salvage ART was guided by
HIV-1 GRT (Student t-test; P < 0.05).
Comparative study
A total of 70 patients were included in
the comparative study, 35 in each sub-
group (G and C). Baseline demographic
data, HIV disease characteristics, and treat-
ment histories of patients from both sub-
groups are summarized in Table 2. There
were no significant differences in either sub-
group for any of the baseline characteris-
tics except for age, which was slightly higher
in subgroup G. The mean times of previous
ART exposure were 50.5 ± 22.8 and 40 ±
22 months for subgroups G and C, respec-
tively. The ART previously used by both
subgroups are presented in Table 3.
The overall retention rate for the cohort
at 24 months was 10 (28.5%) and 9 pa-
tients (25.7%) for subgroups G and C, re-
spectively. A total of 6 patients, 4 from
subgroup G and 2 from subgroup C, dis-
continued participation in the comparative
study for reasons other than having reached
the study end-point. Median and mean times
taken to reach the end-point were 190 and
312.5 days for subgroup G, and 175 and
319.8 days for subgroup C, respectively. A
comparison of survival curves using the
log-rank test demonstrated no significant
differences in mean time to reach the end-
point between groups (Figure 3).
Discussion
The purpose of this study was to evalu-
ate the routine use of HIV-1 GRT in a real-
istic clinical practice setting through the use
of GRT based on expert recommendations
by an infectious disease specialist in a group
of patients with ART failure attended at
AIDS Clinics from Ribeirão Preto, São
Paulo. Due to the characteristics of AIDS
care in Brazil, the impact on ART change
according to expert recommendations
based on GRT results seemed to be a
necessary step to be evaluated in order to
Table 3. Antiretroviral drugs previously administered to 70 patients who had
access to salvage antiretroviral therapy (subgroup G) or not (subgroup C) accord-
ing to expert recommendations based on genotype resistance testing.
Antiretroviral drug Subgroup G (N = 35) Subgroup C (N = 35)
NRTI
AZT (zidovudine) 34 (97%) 35 (100%)
3TC (lamivudine) 32 (91%) 28 (80%)
ddI (didanosine) 26 (74%) 24 (68%)
d4T (stavudine) 22 (62%) 14 (40%)
ddC (zalcitabine) 8 (22%) 6 (17%)
NNRTI
NVP (nevirapine) 4 (11%) 7 (20%)
EFV (efavirenz) 13 (37%) 7 (20%)
PI
SQV (sequinavir) 12 (34%) 10 (28%)
RTV (ritonavir) 14 (40%) 10 (28%)
IDV (indinavir) 28 (80%) 22 (62%)
NFV (nelfinavir) 14 (40%) 8 (22%)
APV (amprenavir) 0 (0%) 0 (0%)
Data are reported as number with percent in parentheses of patients at enrollment.
NRTI = nucleoside reverse-transcriptase inhibitor; NNRTI = non-nucleoside re-
verse-transcriptase inhibitor; PI = protease inhibitor.
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further improve this program.
The successful use of GRT by clinicians in this study
was partially compromised by the delay in the access to
the test results. The mean turn-around time for receiving
the results of the resistance test assay in the present study
was too long. Turn-around time for the resistance test
assay is a parameter never evaluated in clinical trials,
except in the study of Wegner et al. (19) in which the mean
time for the genotype resistance assays was 5 working
days. Time from ordering resistance testing to ART change
should be as short as possible. A delay may represent a
risk of disease worsening since patients with treatment
failure either go without treatment or remain on failing ART
until the resistance test result is available. Clinical deterio-
ration may occur and the mutation profile may change,
causing the result of the resistance test to be useless. This
fact was observed in our study since only approximately
35% of the patients did not reach the end-point of the
study, i.e., they were not on a failing ART.
The long-term efficacy of salvage therapy guided by
GRT was analyzed here in a comparative study involving 70
patients in a realistic clinical setting. No benefit regarding the
clinical parameters was observed in those patients submit-
ted to ART change based on the routine access to HIV-1
genotype testing associated with expert recommendations
when compared to those patients whose ART had been
changed based on their previous history of ART use. Sev-
eral previously published prospective studies have shown a
benefit associated with resistance testing (8-10,20). In a
prospective controlled trial, 153 HIV-1-infected patients fail-
ing on combination drug regimens were randomized to
receive salvage ART guided by GRT with expert advice (78
patients) versus salvage ART guided by clinical judgment
(75 patients). The percentage of patients with HIV-1 RNA
values <500 copies/mL at 4, 8, and 12 weeks was 45 vs 23%
(P = 0.004), 55 vs 25% (P = 0.0001), and 34 vs 22% (P =
0.10), for the GRT versus no-GRT groups, respectively (8).
Similar results were obtained in another prospective study
where 326 HIV-1-infected patients on stable ART and with
treatment failure were randomized to receive salvage ART
guided by GRT (161 patients) versus salvage ART guided
by clinical judgment (165 patients). The proportion of pa-
tients with plasma HIV-1 RNA <400 copies/mL at 24 weeks
was lower for those guided by GRT than for those guided by
clinical judgment (48.5 and 36.2%, respectively; P < 0.05)
(10). In addition, these two studies have suggested that the
benefit of resistance testing is increased when expert inter-
pretation of the resistance test results is used to guide
therapy changes (8,10).
However, another study which included a cohort of 541
HIV-1-infected patients failed to show a relatively short-
term virologic improvement with the use of either pheno-
typic or genotypic resistance tests in combination with
expert advice. Plasma HIV-1 RNA was <200 copies/mL at
week 12 in 35% of patients in the phenotyping group, 44%
in the genotyping group, and 36% in the standard-of-care
group (phenotyping versus standard-of-care, P = 0.918;
genotyping versus standard-of-care, P = 0.120). In a sub-
set analysis of 179 patients experiencing a first protease
inhibitor failure, the percentage of patients achieving HIV-
1 RNA <200 copies/mL was significantly higher in the
genotyping group (65%) than in the phenotyping (45%)
and the standard-of-care groups (45%) (genotyping ver-
sus standard-of-care, P = 0.022) (13). Another study in-
volving 450 participants failed to show that an overall
improvement in the time to refractory treatment failure was
associated with routine access to either genotype or phe-
notype resistance testing when used in a cohort of patients
with a large number of enrollees with limited previous ART
exposure (19).
Most of the previous studies have assessed short-term
changes in viral burden, in contrast to the long-term efficacy
end-point measured in the present study. This study also
differs from previous ones in that the impact of resistance
testing was addressed in a community health care setting,
not in highly structured clinical trial settings. Because of the
unique design of our study, direct outcome comparisons
with other studies are difficult, but extrapolation to other
community health care centers may be relevant.
Access to GRT along with expert recommendations in
Figure 3. Estimated time to end-point curves in the intent-to-treat
analysis involving 70 patients in the following subgroups: pa-
tients submitted to a new antiretroviral therapy guided by geno-
type resistance testing (subgroup G; 35 patients) and patients
submitted to a new antiretroviral therapy guided by clinical man-
agement without resistance testing (subgroup C; 35 patients).
The estimated percentage of subjects not reaching the end-point
is indicated on the y-axis, and the time to end-point is indicated
on the x-axis. A survival comparison using the log-rank test
resulted in a P value >0.05.
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this study was compromised in part by the delay in receiv-
ing the test results, and may have contributed to the lack of
improvement of the long-term virologic outcomes in HIV-
infected patients with treatment failure. At this point, it is
impossible to predict that a better turn-around time would
improve the results but common sense points in this direc-
tion. Measures to improve the time to return the GRT assay
results to the clinicians are under study. Additional analy-
sis of the long-term impact of GRT for salvage ART in
community settings is needed and should be approached
by further studies on this subject, especially in countries
with limited resources.
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